

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era
Tweetorial #1 References

Tweet 3

PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon- β -1a in relapsing MS. *Neurology*. 2001;56:1628-36.
<https://n.neurology.org/content/56/12/1628.long>

Kappos et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018;391(10127):1263-1273
[https://doi.org/10.1016/S0140-6736\(18\)30475-6](https://doi.org/10.1016/S0140-6736(18)30475-6)

Tweet 4

Nazareth TA, et al. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice. *Multiple Sclerosis and Related Disorders*. 2018;26:219-234
<https://doi.org/10.1016/j.msard.2018.09.017>

Tweet 5

Lublin FD, et al. New Multiple Sclerosis Phenotypic Classification. *European Neurology*. 2014;72(Suppl. 1):1-5 <https://doi.org/10.1159/000367614>

Tweet 6

Lublin FD, et al. New Multiple Sclerosis Phenotypic Classification. *European Neurology*. 2014;72(Suppl. 1):1-5 <https://doi.org/10.1159/000367614>

Tweet 8

Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurology*. 2018;17(2):162-173 [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2)

Tweet 9

Miller et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Multiple Sclerosis*. 2008;14:1157-1174
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850590/pdf/10.1177_1352458508096878.pdf

Tweet 11

Langer-Gould A, et al. Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis: A Systematic Review. *Arch Neurol*. 2006;63(12):1686-1691
<https://jamanetwork.com/journals/jamaneurology/fullarticle/792891>

Glossary

<, less than

ASAP, as soon as possible

CIS, clinically isolated syndrome

CNS, central nervous system

CSF, cerebrospinal fluid

DIS, dissemination in space

DIT, dissemination in time

DMT, disease-modifying therapies

MRI, magnetic resonance imaging

MS, multiple sclerosis

NP, nurse practitioner

PA, physician assistant

PPMS, primary-progressive multiple sclerosis

RN, registered nurse

RMS, relapsing multiple sclerosis

RRMS, relapsing-remitting multiple sclerosis

SPMS, secondary-progressive multiple sclerosis

T2, type 2

Vs, versus

w/, with

W/I, within

Y, year(s)

YO, year-old